Sandbox/diarrhea: Difference between revisions

VisualWikitext

Latest revision as of 06:39, 28 July 2020

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Mugilan Poongkunran M.B.B.S [2]

Pathogen Specific

▸ Click on the following categories to expand treatment regimens.^[1]^[2]

Shigella species

▸ Adults

▸ Children

Non-typhi species of Salmonella

▸ Adults

▸ Children

Campylobacter species

▸ Adults

▸ Children

Enterotoxigenic E.coli species

▸ Adults

▸ Children

Enteropathogenic E.coli species

▸ Adults

▸ Children

Enteroinvasive E.coli species

▸ Adults

▸ Children

Enteroaggregative E.coli species

▸ Adults

▸ Children

Enterohemorrhagic E.coli species

▸ Adults

▸ Children

Aeromonas / Plesiomonas

▸ Adults

▸ Children

Yersinia species

▸ Adults

▸ Children

Vibrio cholerae O1 or O139

▸ Adults

▸ Children

Toxigenic Clostridium difficile

▸ Adults

▸ Children

Giardia species

▸ Adults

▸ Children

Cryptosporidium species

▸ Adults

▸ Children

Isospora species

▸ Adults

▸ Children

Cyclospora species

▸ Adults

▸ Children

Microsporidium species

▸ Adults

▸ Children

Entamoeba histolytica

▸ Adults

▸ Children

Immunocompetent patients
Preferred Regimen
▸ Trimethoprim-sulfamethoxazole 160/800 mg orally q12h X 3 days
Alternative Regimen
▸ Ofloxacin 300 mg orally q12h X 3 days OR ▸ Norfloxacin 400 mg orally q12h X 3 days OR ▸ Ciprofloxacin 500 mg orally q12h X 3 days OR ▸ Nalidixic acid 1g orally q24h X 5 days OR ▸ Ceftriaxone 100 mg/kg/day in 2-3 divided doses X 3 days OR ▸ Azithromycin X 3 days
Immunocompromised patients
Preferred Regimen
▸ Trimethoprim-sulfamethoxazole 160/800 mg orally q12h X 7-10 days
Alternative Regimen
▸ Ofloxacin 300 mg orally q12h X 7-10 days OR ▸ Norfloxacin 400 mg orally q12h X 7-10 days OR ▸ Ciprofloxacin 500 mg orally q12h X 7-10 days OR ▸ Nalidixic acid 1g orally q24h X 7-10 days OR ▸ Ceftriaxone 100 mg/kg/day in 2-3 divided doses X 7-10 days OR ▸ Azithromycin X 7-10 days

Immunocompetent patients
Preferred Regimen
▸ Trimethoprim-sulfamethoxazole 5/25 mg/kg orally q12h X 3 days
Alternative Regimen
▸ Nalidixic acid 55 mg/kg/day X 5 days OR ▸ Ceftriaxone 100 mg/kg/day in 2-3 divided doses X 3 days OR ▸ Azithromycin X 3 days
Immunocompromised patients
Preferred Regimen
▸ Trimethoprim-sulfamethoxazole 5/25 mg/kg orally q12h X 7-10 days
Alternative Regimen
▸ Nalidixic acid 55 mg/kg/day X 7-10 days OR ▸ Ceftriaxone 100 mg/kg/day in 2-3 divided doses X 7-10 days OR ▸ Azithromycin X 7-10 days

Immunocompetent
Preferred Regimen
▸ Trimethoprim-sulfamethoxazole 160/800 mg orally q12h X 5-7 days
Alternative Regimen
▸ Ofloxacin 300 mg orally q12h X 5-7 days OR ▸ Norfloxacin 400 mg orally q12h X 5-7 days OR ▸ Ciprofloxacin 500 mg orally q12h X 5-7 days OR ▸ Ceftriaxone 100 mg/kg/day in 2-3 divided doses X 5-7 days
Immunocompromised patients
Preferred Regimen
▸ Trimethoprim-sulfamethoxazole 160/800 mg orally q12h X 14 days
Alternative Regimen
▸ Ofloxacin 300 mg orally q12h X 14 days OR ▸ Norfloxacin 400 mg orally q12h X 14 days OR ▸ Ciprofloxacin 500 mg orally q12h X 14 days OR ▸ Ceftriaxone 100 mg/kg/day in 2-3 divided doses X 14 days

Immunocompetent
Preferred Regimen
▸ Trimethoprim-sulfamethoxazole 5/25 mg/kg orally q12h X 5-7 days
Alternative Regimen
▸ Ceftriaxone 100 mg/kg/day in 2-3 divided doses X 5-7 days
Immunocompromised patients
Preferred Regimen
▸ Trimethoprim-sulfamethoxazole 5/25 mg/kg orally q12h X 14 days
Alternative Regimen
▸ Ceftriaxone 100 mg/kg/day in 2-3 divided doses X 14 days

Immunocompetent
Preferred Regimen
▸ Erythromycin 500 mg orally q12h X 5 days
Immunocompromised
▸ Erythromycin 500 mg orally q12h X extended period

Immunocompetent
Preferred Regimen
▸ Erythromycin 500 mg orally q12h X 5 days
Immunocompromised
▸ Erythromycin 500 mg orally q12h X extended period

Immunocompetent patients
Preferred Regimen
▸ Trimethoprim-sulfamethoxazole 160/800 mg orally q12h X 3 days
Alternative Regimen
▸ Ofloxacin 300 mg orally q12h X 3 days OR ▸ Norfloxacin 400 mg orally q12h X 3 days OR ▸ Ciprofloxacin 500 mg orally q12h X 3 days
Immunocompromised patients
Preferred Regimen
▸ Trimethoprim-sulfamethoxazole 160/800 mg orally q12h X 5-7 days
Alternative Regimen
▸ Ofloxacin 300 mg orally q12h X 5-7 days OR ▸ Norfloxacin 400 mg orally q12h X 5-7 days OR ▸ Ciprofloxacin 500 mg orally q12h X 5-7 days

Immunocompetent patients
Preferred Regimen
▸ Trimethoprim-sulfamethoxazole 5/25 mg orally q12h X 3 days
Immunocompromised patients
Preferred Regimen
▸ Trimethoprim-sulfamethoxazole 5/25 mg orally q12h X 5-7 days

Immunocompetent patients
Preferred Regimen
▸ Erythromycin 500 mg orally q12h X 5 days
Immunocompromised patients
Preferred Regimen
▸ Trimethoprim-sulfamethoxazole 160/800 mg orally q12h X 5-7 days
Alternative Regimen
▸ Ofloxacin 300 mg orally q12h X 5-7 days OR ▸ Norfloxacin 400 mg orally q12h X 5-7 days OR ▸ Ciprofloxacin 500 mg orally q12h X 5-7 days

Immunocompetent patients
Preferred Regimen
▸ Erythromycin 500 mg orally q12h X 5 days
Immunocompromised patients
Preferred Regimen
▸ Trimethoprim-sulfamethoxazole 5/25 mg orally q12h X 5-7 days

Immunocompetent patients
Preferred Regimen
▸ Erythromycin 500 mg orally q12h X 5 days
Immunocompromised patients
Preferred Regimen
▸ Trimethoprim-sulfamethoxazole 160/800 mg orally q12h X 5-7 days
Alternative Regimen
▸ Ofloxacin 300 mg orally q12h X 5-7 days OR ▸ Norfloxacin 400 mg orally q12h X 5-7 days OR ▸ Ciprofloxacin 500 mg orally q12h X 5-7 days

Immunocompetent patients
Preferred Regimen
▸ Erythromycin 500 mg orally q12h X 5 days
Immunocompromised patients
Preferred Regimen
▸ Trimethoprim-sulfamethoxazole 5/25 mg orally q12h X 5-7 days

Immunocompetent patients
Preferred Regimen
▸ Unknown
Immunocompromised patients
Preferred Regimen (For ETEC)
▸ Ofloxacin 300 mg orally q12h X 5-7 days OR ▸ Norfloxacin 400 mg orally q12h X 5-7 days OR ▸ Ciprofloxacin 500 mg orally q12h X 5-7 days

Immunocompetent patients
Preferred Regimen
▸ Unknown
Immunocompromised patients
Preferred Regimen
▸ Unknown

Immunocompetent patients
Preferred Regimen
▸ Role of antibiotics unclear, and administration should be avoided
Immunocompromised patients
Preferred Regimen
▸ Role of antibiotics unclear, and administration should be avoided

Immunocompetent patients
Preferred Regimen
▸ Role of antibiotics unclear, and administration should be avoided
Immunocompromised patients
Preferred Regimen
▸ Role of antibiotics unclear, and administration should be avoided

Immunocompetent patients
Preferred Regimen
▸ Trimethoprim-sulfamethoxazole 160/800 mg orally q12h X 3 days
Alternative Regimen
▸ Ofloxacin 300 mg orally q12h X 3 days OR ▸ Norfloxacin 400 mg orally q12h X 3 days OR ▸ Ciprofloxacin 500 mg orally q12h X 3 days
Immunocompromised patients
Preferred Regimen
▸ Trimethoprim-sulfamethoxazole 160/800 mg orally q12h X 5-7 days
Alternative Regimen
▸ Ofloxacin 300 mg orally q12h X 5-7 days OR ▸ Norfloxacin 400 mg orally q12h X 5-7 days OR ▸ Ciprofloxacin 500 mg orally q12h X 5-7 days

Immunocompetent patients
Preferred Regimen
▸ Trimethoprim-sulfamethoxazole 5/25 mg orally q12h X 3 days
Immunocompromised patients
Preferred Regimen
▸ Trimethoprim-sulfamethoxazole 5/25 mg orally q12h X 5-7 days

Immunocompetent patients
Preferred Regimen (Only for severe infections or bacteremia)
▸ Doxycycline 300 mg orally single dose OR ▸ Tetracycline 500 mg orally q6h X 3 days
Alternative Regimen
▸ Trimethoprim-sulfamethoxazole 160/800 mg orally q12h X 5-7 days OR ▸ Ofloxacin 300 mg orally q12h X 5-7 days OR ▸ Norfloxacin 400 mg orally q12h X 5-7 days OR ▸ Ciprofloxacin 500 mg orally q12h X 5-7 days
Immunocompromised patients
Preferred Regimen
▸ Doxycycline 300 mg orally single dose PLUS ▸ Tetracycline 500 mg orally q6h X 3 days
Alternative Regimen
▸ Trimethoprim-sulfamethoxazole 160/800 mg orally q12h X 5-7 days OR ▸ Ofloxacin 300 mg orally q12h X 5-7 days OR ▸ Norfloxacin 400 mg orally q12h X 5-7 days OR ▸ Ciprofloxacin 500 mg orally q12h X 5-7 days

Immunocompetent patients
Preferred Regimen (Only for severe infections or bacteremia)
▸ Doxycycline 300 mg orally single dose OR ▸ Tetracycline 500 mg orally q6h X 3 days
Alternative Regimen
▸ Trimethoprim-sulfamethoxazole 5/25 mg orally q12h X 5-7 days
Immunocompromised patients
Preferred Regimen
▸ Doxycycline 300 mg orally single dose PLUS ▸ Tetracycline 500 mg orally q6h X 3 days
Alternative Regimen
▸ Trimethoprim-sulfamethoxazole 5/25 mg orally q12h X 5-7 days

Immunocompetent patients
Preferred Regimen
▸ Doxycycline 300 mg orally single dose OR ▸ Tetracycline 500 mg orally q6h X 3 days
Alternative Regimen
▸ Trimethoprim-sulfamethoxazole 160/800 mg orally q12h X 3 days OR ▸ Ofloxacin 300 mg orally q12h X 3 days OR ▸ Norfloxacin 400 mg orally q12h X 3 days OR ▸ Ciprofloxacin 500 mg orally q12h X 3 days
Immunocompromised patients
Preferred Regimen
▸ Doxycycline 300 mg orally single dose PLUS ▸ Tetracycline 500 mg orally q6h X 3 days
Alternative Regimen
▸ Trimethoprim-sulfamethoxazole 160/800 mg orally q12h X 5-7 days OR ▸ Ofloxacin 300 mg orally q12h X 5-7 days OR ▸ Norfloxacin 400 mg orally q12h X 5-7 days OR ▸ Ciprofloxacin 500 mg orally q12h X 5-7 days

Immunocompetent patients
Preferred Regimen
▸ Doxycycline 300 mg orally single dose OR ▸ Tetracycline 500 mg orally q6h X 3 days
Alternative Regimen
▸ Trimethoprim-sulfamethoxazole 5/25 mg orally q12h X 5-7 days
Immunocompromised patients
Preferred Regimen
▸ Doxycycline 300 mg orally single dose PLUS ▸ Tetracycline 500 mg orally q6h X 3 days
Alternative Regimen
▸ Trimethoprim-sulfamethoxazole 5/25 mg orally q12h X 5-7 days

Immunocompetent patients
Preferred Regimen
▸ Metronidazole 250 mg orally q6h X 10 days OR ▸ Metronidazole 500 mg orally q8h X 10 days
Immunocompromised patients
Preferred Regimen
▸ Doxycycline 300 mg orally single dose PLUS ▸ Tetracycline 500 mg orally q6h X 3 days
Alternative Regimen
▸ Trimethoprim-sulfamethoxazole 160/800 mg orally q12h X 5-7 days OR ▸ Ofloxacin 300 mg orally q12h X 5-7 days OR ▸ Norfloxacin 400 mg orally q12h X 5-7 days OR ▸ Ciprofloxacin 500 mg orally q12h X 5-7 days

Immunocompetent patients
Preferred Regimen
▸ Metronidazole 250 mg orally q6h X 10 days OR ▸ Metronidazole 500 mg orally q8h X 10 days
Immunocompromised patients
Preferred Regimen
▸ Doxycycline 300 mg orally single dose PLUS ▸ Tetracycline 500 mg orally q6h X 3 days
Alternative Regimen
▸ Trimethoprim-sulfamethoxazole 5/25 mg orally q12h X 5-7 days

Immunocompetent patients
Preferred Regimen
▸ Metronidazole 250-750 mg orally q8h X 7-10 days
Immunocompromised patients
Preferred Regimen
▸ Doxycycline 300 mg orally single dose PLUS ▸ Tetracycline 500 mg orally q6h X 3 days
Alternative Regimen
▸ Trimethoprim-sulfamethoxazole 160/800 mg orally q12h X 5-7 days OR ▸ Ofloxacin 300 mg orally q12h X 5-7 days OR ▸ Norfloxacin 400 mg orally q12h X 5-7 days OR ▸ Ciprofloxacin 500 mg orally q12h X 5-7 days

Immunocompetent patients
Preferred Regimen
▸ Metronidazole 250-750 mg orally q8h X 7-10 days
Immunocompromised patients
Preferred Regimen
▸ Doxycycline 300 mg orally single dose PLUS ▸ Tetracycline 500 mg orally q6h X 3 days
Alternative Regimen
▸ Trimethoprim-sulfamethoxazole 5/25 mg orally q12h X 5-7 days

Immunocompetent patients
Preferred Regimen (only if severe)
▸ Paromomycin 500 mg orally q8h X 7 days
Immunocompromised patients
Preferred Regimen
▸ Paromomycin 500 mg orally q8h X 14-28 days THEN ▸ Paromomycin 500 mg orally q12h X if needed

Immunocompetent patients
Preferred Regimen (only if severe)
▸ Paromomycin 500 mg orally q8h X 7 days
Immunocompromised patients
Preferred Regimen
▸ Paromomycin 500 mg orally q8h X 14-28 days THEN ▸ Paromomycin 500 mg orally q12h X if needed

Immunocompetent patients
Preferred Regimen
▸ Trimethoprim-sulfamethoxazole 160/800 mg orally q12h X 7-10 days
Immunocompromised patients
Preferred Regimen
▸ Trimethoprim-sulfamethoxazole 160/800 mg orally q6h X 10 days THEN ▸ Trimethoprim-sulfamethoxazole 160/800 mg orally thrice weekly indefinitely
Alternative Regimen (indefinitely for AIDS patients)
▸ Sulfadoxine 500 mg PLUS ▸ Pyrimethamine 25 mg

Immunocompetent patients
Preferred Regimen
▸ Trimethoprim-sulfamethoxazole 5/25 mg orally q12h X 7-10 days
Immunocompromised patients
Preferred Regimen
▸ Trimethoprim-sulfamethoxazole 5/25 mg orally q6h X 10 days THEN ▸ Trimethoprim-sulfamethoxazole 5/25 mg orally thrice weekly indefinitely
Alternative Regimen (indefinitely for AIDS patients)
▸ Sulfadoxine 500 mg PLUS ▸ Pyrimethamine 25 mg

Immunocompetent patients
Preferred Regimen
▸ Trimethoprim-sulfamethoxazole 160/800 mg orally q12h X 7 days
Immunocompromised patients
Preferred Regimen
▸ Trimethoprim-sulfamethoxazole 160/800 mg orally q6h X 10 days THEN ▸ Trimethoprim-sulfamethoxazole 160/800 mg orally thrice weekly indefinitely

Immunocompetent patients
Preferred Regimen
▸ Trimethoprim-sulfamethoxazole 5/25 mg orally q12h X 7 days
Immunocompromised patients
Preferred Regimen
▸ Trimethoprim-sulfamethoxazole 5/25 mg orally q6h X 10 days THEN ▸ Trimethoprim-sulfamethoxazole 5/25 mg orally thrice weekly indefinitely

Immunocompetent patients
Preferred Regimen
▸ Not determined
Immunocompromised patients
Preferred Regimen
▸ Albendazole 400 mg orally q12h X 21 days

Immunocompetent patients
Preferred Regimen
▸ Not determined
Immunocompromised patients
Preferred Regimen
▸ Albendazole 400 mg orally q12h X 21 days

Immunocompetent patients
Preferred Regimen
▸ Metronidazole 750 mg orally q8h X 5-10 days PLUS ▸ Diiodohydroxyquin 650 mg orally q8h X 20 days
Alternative Regimen
▸ Metronidazole 750 mg orally q8h X 5-10 days PLUS ▸ Paromomycin 500 mg orally q8h X 7 days
Immunocompromised patients
Preferred Regimen
▸ Metronidazole 750 mg orally q8h X 5-10 days PLUS ▸ Diiodohydroxyquin 650 mg orally q8h X 20 days
Alternative Regimen
▸ Metronidazole 750 mg orally q8h X 5-10 days PLUS ▸ Paromomycin 500 mg orally q8h X 7 days

Immunocompetent patients
Preferred Regimen
▸ Metronidazole 750 mg orally q8h X 5-10 days PLUS ▸ Diiodohydroxyquin 650 mg orally q8h X 20 days
Alternative Regimen
▸ Metronidazole 750 mg orally q8h X 5-10 days PLUS ▸ Paromomycin 500 mg orally q8h X 7 days
Immunocompromised patients
Preferred Regimen
▸ Metronidazole 750 mg orally q8h X 5-10 days PLUS ▸ Diiodohydroxyquin 650 mg orally q8h X 20 days
Alternative Regimen
▸ Metronidazole 750 mg orally q8h X 5-10 days PLUS ▸ Paromomycin 500 mg orally q8h X 7 days

References

↑ Guerrant RL, Van Gilder T, Steiner TS, Thielman NM, Slutsker L, Tauxe RV; et al. (2001). "Practice guidelines for the management of infectious diarrhea". Clin Infect Dis. 32 (3): 331–51. doi:10.1086/318514. PMID 11170940.
↑ Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC; et al. (2010). "Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA)". Infect Control Hosp Epidemiol. 31 (5): 431–55. doi:10.1086/651706. PMID 20307191.

[pmid11170940-1] Guerrant RL, Van Gilder T, Steiner TS, Thielman NM, Slutsker L, Tauxe RV; et al. (2001). "Practice guidelines for the management of infectious diarrhea". Clin Infect Dis. 32 (3): 331–51. doi:10.1086/318514. PMID 11170940.

[pmid20307191-2] Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC; et al. (2010). "Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA)". Infect Control Hosp Epidemiol. 31 (5): 431–55. doi:10.1086/651706. PMID 20307191.

[1]

[2]

@@ Line 2: / Line 2: @@
 {{CMG}}; {{M.P}}
-==Antibiotic Therapy==
+===Pathogen Specific===
-==Pathogen Specific==
+<SMALL><font color="#FF4C4C"> '''▸ Click on the following categories to expand treatment regimens.'''<ref name="pmid11170940">{{cite journal| author=Guerrant RL, Van Gilder T, Steiner TS, Thielman NM, Slutsker L, Tauxe RV et al.| title=Practice guidelines for the management of infectious diarrhea. | journal=Clin Infect Dis | year= 2001 | volume= 32 | issue= 3 | pages= 331-51 | pmid=11170940 | doi=10.1086/318514 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11170940  }} </ref><ref name="pmid20307191">{{cite journal| author=Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC et al.| title=Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). | journal=Infect Control Hosp Epidemiol | year= 2010 | volume= 31 | issue= 5 | pages= 431-55 | pmid=20307191 | doi=10.1086/651706 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20307191  }} </ref></font></SMALL>
-<SMALL><font color="#FF4C4C"> '''▸ Click on the following categories to expand treatment regimens.'''<ref name="pmid11170940">{{cite journal| author=Guerrant RL, Van Gilder T, Steiner TS, Thielman NM, Slutsker L, Tauxe RV et al.| title=Practice guidelines for the management of infectious diarrhea. | journal=Clin Infect Dis | year= 2001 | volume= 32 | issue= 3 | pages= 331-51 | pmid=11170940 | doi=10.1086/318514 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11170940  }} </ref><ref name="pmid20307191">{{cite journal| author=Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC et al.| title=Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). | journal=Infect Control Hosp Epidemiol | year= 2010 | volume= 31 | issue= 5 | pages= 431-55 | pmid=20307191 | doi=10.1086/651706 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20307191  }} </ref>
 {|
@@ Line 63: / Line 62: @@
 </div>
-<div style="border-radius: 0 0 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #A1BCDD; text-align: center;">
+<div style="border-radius: 5px 5px 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #A1BCDD; text-align: center;">
+<font color="#FFF">
+'''Enterotoxigenic E.coli species'''
+</font>
+</div>
+<div class="mw-customtoggle-table51" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
 <font color="#FFF">
-'''Escherichia coli species'''
+&nbsp;&nbsp;▸&nbsp;&nbsp;'''Adults'''
 </font>
 </div>
@@ Line 71: / Line 76: @@
 <div class="mw-customtoggle-table52" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
 <font color="#FFF">
-&nbsp;&nbsp;▸&nbsp;&nbsp;'''Enterotoxigenic '''
+&nbsp;&nbsp;▸&nbsp;&nbsp;'''Children'''
+</font>
+</div>
+<div style="border-radius: 5px 5px 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #A1BCDD; text-align: center;">
+<font color="#FFF">
+'''Enteropathogenic E.coli species'''
 </font>
 </div>
@@ Line 77: / Line 88: @@
 <div class="mw-customtoggle-table53" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
 <font color="#FFF">
-&nbsp;&nbsp;▸&nbsp;&nbsp;'''Enteropathogenic'''
+&nbsp;&nbsp;▸&nbsp;&nbsp;'''Adults'''
+</font>
+</div>
+<div class="mw-customtoggle-table54" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
+<font color="#FFF">
+&nbsp;&nbsp;▸&nbsp;&nbsp;'''Children'''
+</font>
+</div>
+<div style="border-radius: 5px 5px 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #A1BCDD; text-align: center;">
+<font color="#FFF">
+'''Enteroinvasive E.coli species'''
+</font>
+</div>
+<div class="mw-customtoggle-table55" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
+<font color="#FFF">
+&nbsp;&nbsp;▸&nbsp;&nbsp;'''Adults'''
+</font>
+</div>
+<div class="mw-customtoggle-table56" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
+<font color="#FFF">
+&nbsp;&nbsp;▸&nbsp;&nbsp;'''Children'''
+</font>
+</div>
+<div style="border-radius: 5px 5px 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #A1BCDD; text-align: center;">
+<font color="#FFF">
+'''Enteroaggregative E.coli species'''
 </font>
 </div>
-<div class="mw-customtoggle-table52" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
+<div class="mw-customtoggle-table57" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
+<font color="#FFF">
+&nbsp;&nbsp;▸&nbsp;&nbsp;'''Adults'''
+</font>
+</div>
+<div class="mw-customtoggle-table58" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
+<font color="#FFF">
+&nbsp;&nbsp;▸&nbsp;&nbsp;'''Children'''
+</font>
+</div>
+<div style="border-radius: 5px 5px 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #A1BCDD; text-align: center;">
 <font color="#FFF">
-&nbsp;&nbsp;▸&nbsp;&nbsp;'''Enteroinvasive'''
+'''Enterohemorrhagic E.coli species'''
 </font>
 </div>
-<div class="mw-customtoggle-table53" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
+<div class="mw-customtoggle-table59" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
 <font color="#FFF">
-&nbsp;&nbsp;▸&nbsp;&nbsp;'''Enteroaggregative'''
+&nbsp;&nbsp;▸&nbsp;&nbsp;'''Adults'''
 </font>
 </div>
-<div class="mw-customtoggle-table53" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
+<div class="mw-customtoggle-table60" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
 <font color="#FFF">
-&nbsp;&nbsp;▸&nbsp;&nbsp;'''Enterohemorrhagic (STEC)'''
+&nbsp;&nbsp;▸&nbsp;&nbsp;'''Children'''
 </font>
 </div>
@@ Line 105: / Line 158: @@
 </div>
-<div class="mw-customtoggle-table32" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
+<div class="mw-customtoggle-table61" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
 <font color="#FFF">
 &nbsp;&nbsp;▸&nbsp;&nbsp;'''Adults'''
@@ Line 111: / Line 164: @@
 </div>
-<div class="mw-customtoggle-table33" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
+<div class="mw-customtoggle-table62" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
 <font color="#FFF">
 &nbsp;&nbsp;▸&nbsp;&nbsp;'''Children'''
@@ Line 123: / Line 176: @@
 </div>
-<div class="mw-customtoggle-table62" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
+<div class="mw-customtoggle-table63" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
 <font color="#FFF">
 &nbsp;&nbsp;▸&nbsp;&nbsp;'''Adults'''
@@ Line 129: / Line 182: @@
 </div>
-<div class="mw-customtoggle-table63" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
+<div class="mw-customtoggle-table64" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
 <font color="#FFF">
 &nbsp;&nbsp;▸&nbsp;&nbsp;'''Children'''
@@ Line 141: / Line 194: @@
 </div>
-<div class="mw-customtoggle-table42" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
+<div class="mw-customtoggle-table65" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
 <font color="#FFF">
 &nbsp;&nbsp;▸&nbsp;&nbsp;'''Adults'''
@@ Line 147: / Line 200: @@
 </div>
-<div class="mw-customtoggle-table43" style="cursor: pointer; border-radius: 0 0 5px 5px; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
+<div class="mw-customtoggle-table66" style="cursor: pointer; border-radius: 0 0 5px 5px; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
 <font color="#FFF">
 &nbsp;&nbsp;▸&nbsp;&nbsp;'''Children'''
@@ Line 159: / Line 212: @@
 </div>
-<div class="mw-customtoggle-table42" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
+<div class="mw-customtoggle-table67" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
 <font color="#FFF">
 &nbsp;&nbsp;▸&nbsp;&nbsp;'''Adults'''
@@ Line 165: / Line 218: @@
 </div>
-<div class="mw-customtoggle-table43" style="cursor: pointer; border-radius: 0 0 5px 5px; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
+<div class="mw-customtoggle-table68" style="cursor: pointer; border-radius: 0 0 5px 5px; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
 <font color="#FFF">
 &nbsp;&nbsp;▸&nbsp;&nbsp;'''Children'''
@@ Line 173: / Line 226: @@
 <div style="border-radius: 0 0 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #A1BCDD; text-align: center;">
 <font color="#FFF">
-'''Parasites'''
+'''Giardia species'''
 </font>
 </div>
-<div class="mw-customtoggle-table42" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
+<div class="mw-customtoggle-table88" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
 <font color="#FFF">
-&nbsp;&nbsp;▸&nbsp;&nbsp;'''Giardia'''
+&nbsp;&nbsp;▸&nbsp;&nbsp;'''Adults'''
 </font>
 </div>
-<div class="mw-customtoggle-table43" style="cursor: pointer; border-radius: 0 0 5px 5px; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
+<div class="mw-customtoggle-table89" style="cursor: pointer; border-radius: 0 0 5px 5px; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
 <font color="#FFF">
-&nbsp;&nbsp;▸&nbsp;&nbsp;'''Cryptosporidium species'''
+&nbsp;&nbsp;▸&nbsp;&nbsp;'''Children'''
 </font>
 </div>
-<div class="mw-customtoggle-table43" style="cursor: pointer; border-radius: 0 0 5px 5px; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
+<div style="border-radius: 0 0 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #A1BCDD; text-align: center;">
 <font color="#FFF">
-&nbsp;&nbsp;▸&nbsp;&nbsp;'''Isospora species'''
+'''Cryptosporidium species'''
 </font>
 </div>
-<div class="mw-customtoggle-table43" style="cursor: pointer; border-radius: 0 0 5px 5px; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
+<div class="mw-customtoggle-table70" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
 <font color="#FFF">
-&nbsp;&nbsp;▸&nbsp;&nbsp;'''Cyclospora species'''
+&nbsp;&nbsp;▸&nbsp;&nbsp;'''Adults'''
 </font>
 </div>
-<div class="mw-customtoggle-table43" style="cursor: pointer; border-radius: 0 0 5px 5px; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
+<div class="mw-customtoggle-table71" style="cursor: pointer; border-radius: 0 0 5px 5px; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
 <font color="#FFF">
-&nbsp;&nbsp;▸&nbsp;&nbsp;'''Microsporidium species'''
+&nbsp;&nbsp;▸&nbsp;&nbsp;'''Children'''
 </font>
 </div>
-<div class="mw-customtoggle-table43" style="cursor: pointer; border-radius: 0 0 5px 5px; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
+<div style="border-radius: 0 0 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #A1BCDD; text-align: center;">
 <font color="#FFF">
-&nbsp;&nbsp;▸&nbsp;&nbsp;'''Entamoeba histolytica'''
+'''Isospora species'''
+</font>
+</div>
+<div class="mw-customtoggle-table72" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
+<font color="#FFF">
+&nbsp;&nbsp;▸&nbsp;&nbsp;'''Adults'''
+</font>
+</div>
+<div class="mw-customtoggle-table73" style="cursor: pointer; border-radius: 0 0 5px 5px; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
+<font color="#FFF">
+&nbsp;&nbsp;▸&nbsp;&nbsp;'''Children'''
+</font>
+</div>
+<div style="border-radius: 0 0 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #A1BCDD; text-align: center;">
+<font color="#FFF">
+'''Cyclospora species'''
+</font>
+</div>
+<div class="mw-customtoggle-table74" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
+<font color="#FFF">
+&nbsp;&nbsp;▸&nbsp;&nbsp;'''Adults'''
+</font>
+</div>
+<div class="mw-customtoggle-table75" style="cursor: pointer; border-radius: 0 0 5px 5px; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
+<font color="#FFF">
+&nbsp;&nbsp;▸&nbsp;&nbsp;'''Children'''
+</font>
+</div>
+<div style="border-radius: 0 0 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #A1BCDD; text-align: center;">
+<font color="#FFF">
+'''Microsporidium species'''
+</font>
+</div>
+<div class="mw-customtoggle-table76" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
+<font color="#FFF">
+&nbsp;&nbsp;▸&nbsp;&nbsp;'''Adults'''
+</font>
+</div>
+<div class="mw-customtoggle-table77" style="cursor: pointer; border-radius: 0 0 5px 5px; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
+<font color="#FFF">
+&nbsp;&nbsp;▸&nbsp;&nbsp;'''Children'''
+</font>
+</div>
+<div style="border-radius: 0 0 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #A1BCDD; text-align: center;">
+<font color="#FFF">
+'''Entamoeba histolytica'''
+</font>
+</div>
+<div class="mw-customtoggle-table78" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
+<font color="#FFF">
+&nbsp;&nbsp;▸&nbsp;&nbsp;'''Adults'''
+</font>
+</div>
+<div class="mw-customtoggle-table79" style="cursor: pointer; border-radius: 0 0 5px 5px; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
+<font color="#FFF">
+&nbsp;&nbsp;▸&nbsp;&nbsp;'''Children'''
 </font>
 </div>
@@ Line 226: / Line 345: @@
 | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
 |-
-| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ofloxacin]] 300 mg orally q12h X 3 days'''''<BR> OR <BR> ▸ '''''[[Norfloxacin]] 400 mg orally q12h X 3 days'''''<BR> OR <BR> ▸ '''''[[Ciprofloxacin]] 500 mg orally q12h X 3 days'''''<BR> OR <BR> ▸ '''''[[Nalidixic acid]] 1g orally q24h X 5 days'''''<BR> OR <BR> ▸ '''''[[Ceftriaxone]] X 3 days'''''<BR> OR <BR> ▸ '''''[[Azithromycin]] X 3 days'''''
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ofloxacin]] 300 mg orally q12h X 3 days'''''<BR> OR <BR> ▸ '''''[[Norfloxacin]] 400 mg orally q12h X 3 days'''''<BR> OR <BR> ▸ '''''[[Ciprofloxacin]] 500 mg orally q12h X 3 days'''''<BR> OR <BR> ▸ '''''[[Nalidixic acid]] 1g orally q24h X 5 days'''''<BR> OR <BR> ▸ '''''[[Ceftriaxone]] 100 mg/kg/day in 2-3 divided doses X 3 days'''''<BR> OR <BR> ▸ '''''[[Azithromycin]] X 3 days'''''
 |-
 ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
@@ Line 236: / Line 355: @@
 | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
 |-
-| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ofloxacin]] 300 mg orally q12h X 7-10 days'''''<BR> OR <BR> ▸ '''''[[Norfloxacin]] 400 mg orally q12h X 7-10 days'''''<BR> OR <BR> ▸ '''''[[Ciprofloxacin]] 500 mg orally q12h X 7-10 days'''''<BR> OR <BR> ▸ '''''[[Nalidixic acid]] 1g orally q24h X 7-10 days'''''<BR> OR <BR> ▸ '''''[[Ceftriaxone]] X 7-10 days'''''<BR> OR <BR> ▸ '''''[[Azithromycin]] X 7-10 days'''''
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ofloxacin]] 300 mg orally q12h X 7-10 days'''''<BR> OR <BR> ▸ '''''[[Norfloxacin]] 400 mg orally q12h X 7-10 days'''''<BR> OR <BR> ▸ '''''[[Ciprofloxacin]] 500 mg orally q12h X 7-10 days'''''<BR> OR <BR> ▸ '''''[[Nalidixic acid]] 1g orally q24h X 7-10 days'''''<BR> OR <BR> ▸ '''''[[Ceftriaxone]] 100 mg/kg/day in 2-3 divided doses X 7-10 days'''''<BR> OR <BR> ▸ '''''[[Azithromycin]] X 7-10 days'''''
 |-
 |}
@@ Line 252: / Line 371: @@
 | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
 |-
-| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Nalidixic acid]] 55 mg/kg/day X 5 days'''''<BR> OR <BR> ▸ '''''[[Ceftriaxone]] X 3 days'''''<BR> OR <BR> ▸ '''''[[Azithromycin]] X 3 days'''''
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Nalidixic acid]] 55 mg/kg/day X 5 days'''''<BR> OR <BR> ▸ '''''[[Ceftriaxone]] 100 mg/kg/day in 2-3 divided doses X 3 days'''''<BR> OR <BR> ▸ '''''[[Azithromycin]] X 3 days'''''
 |-
 ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
@@ Line 262: / Line 381: @@
 | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
 |-
-| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Nalidixic acid]] 55 mg/kg/day X 7-10 days'''''<BR> OR <BR> ▸ '''''[[Ceftriaxone]] X 7-10 days'''''<BR> OR <BR> ▸ '''''[[Azithromycin]] X 7-10 days'''''
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Nalidixic acid]] 55 mg/kg/day X 7-10 days'''''<BR> OR <BR> ▸ '''''[[Ceftriaxone]] 100 mg/kg/day in 2-3 divided doses X 7-10 days'''''<BR> OR <BR> ▸ '''''[[Azithromycin]] X 7-10 days'''''
 |-
 |}
@@ Line 270: / Line 389: @@
 | valign=top |
 {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
-! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Early (not yet infected)}}
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompetent}}
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]]  160/800 mg orally q12h X 5-7 days'''''
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ofloxacin]] 300 mg orally q12h X 5-7 days'''''<BR> OR <BR> ▸ '''''[[Norfloxacin]] 400 mg orally q12h X 5-7 days'''''<BR> OR <BR> ▸ '''''[[Ciprofloxacin]] 500 mg orally q12h X 5-7 days'''''<BR> OR <BR> ▸ '''''[[Ceftriaxone]] 100 mg/kg/day in 2-3 divided doses X 5-7 days'''''
+|-
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]]  160/800 mg orally q12h X 14 days'''''
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ofloxacin]] 300 mg orally q12h X 14 days'''''<BR> OR <BR> ▸ '''''[[Norfloxacin]] 400 mg orally q12h X 14 days'''''<BR> OR <BR> ▸ '''''[[Ciprofloxacin]] 500 mg orally q12h X 14 days'''''<BR> OR <BR> ▸ '''''[[Ceftriaxone]] 100 mg/kg/day in 2-3 divided doses X 14 days'''''
+|-
+|}
+|}
+{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table13" style="background: #FFFFFF;"
+| valign=top |
+{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompetent}}
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]]  5/25 mg/kg orally q12h X 5-7 days'''''
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ceftriaxone]] 100 mg/kg/day in 2-3 divided doses X 5-7 days'''''
+|-
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]]  5/25 mg/kg orally q12h X 14 days'''''
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ceftriaxone]] 100 mg/kg/day in 2-3 divided doses X 14 days'''''
+|-
+|}
+|}
+{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table22" style="background: #FFFFFF;"
+| valign=top |
+{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompetent}}
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Erythromycin]] 500 mg orally q12h X 5 days'''''
+|-
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised}}
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Erythromycin]] 500 mg orally q12h X extended period'''''
+|-
+|}
+|}
+{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table23" style="background: #FFFFFF;"
+| valign=top |
+{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompetent}}
 |-
 | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
 |-
-| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Amoxicillin-clavulanate]] 875/125 mg orally q12h'''''<BR> OR <BR> ▸ '''''[[Amoxicillin-clavulanate]] 500/125 mg orally q8h'''''
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Erythromycin]] 500 mg orally q12h X 5 days'''''
 |-
-| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen (beta-lactam allergy)'''''
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised}}
 |-
-| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Clindamycin]] 300 mg orally q6h'''''
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Erythromycin]] 500 mg orally q12h X extended period'''''
 |-
-| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS
+|}
+|}
+{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table51" style="background: #FFFFFF;"
+| valign=top |
+{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompetent patients}}
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]]  160/800 mg orally q12h X 3 days'''''
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
 |-
-| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ciprofloxacin]] 500 to 750 mg orally q12h'''''
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ofloxacin]] 300 mg orally q12h X 3 days'''''<BR> OR <BR> ▸ '''''[[Norfloxacin]] 400 mg orally q12h X 3 days'''''<BR> OR <BR> ▸ '''''[[Ciprofloxacin]] 500 mg orally q12h X 3 days'''''
 |-
-! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Late (infected)}}
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
 |-
 | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
 |-
-| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ampicillin sulbactam]] 1.5 to 3 g IV q6-8h'''''<BR> OR <BR> ▸ '''''[[Piperacillin-tazobactam]] 3.375 gm IV q6-8h'''''<BR> OR <BR> ▸ '''''[[Ertapenem]] 1 gm IV q24h'''''<BR> OR <BR> ▸ '''''[[Imipenem]]-[[Cilastin]] 1 gm IV q6-8h'''''<BR> OR <BR> ▸ '''''[[Imipenem]]-[[Cilastin]] 1 gm IV q6-8h'''''<BR> OR <BR> ▸ '''''[[Meropenem]] 1 gm IV q8h'''''
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]]  160/800 mg orally q12h X 5-7 days'''''
 |-
-| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen (beta-lactam allergy)'''''
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ofloxacin]] 300 mg orally q12h X 5-7 days'''''<BR> OR <BR> ▸ '''''[[Norfloxacin]] 400 mg orally q12h X 5-7 days'''''<BR> OR <BR> ▸ '''''[[Ciprofloxacin]] 500 mg orally q12h X 5-7 days'''''
 |-
-| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Cefazolin]] 1 gm IV q8h'''''<BR> OR <BR> ▸ '''''[[Cefuroxime]] 1 gm IV q24h'''''<BR> OR <BR> ▸ '''''[[Cefoxitin]] 1 gm IV q6-8h'''''<BR> OR <BR>▸ '''''[[Ceftriaxone sodium]] 1 gm IV q12h'''''<BR> OR <BR>▸ '''''[[Cefotaxime]] 2 gm IV q6h'''''<BR> OR <BR>▸ '''''[[Ciprofloxacin]] 400 mg IV q12h'''''<BR> OR <BR>▸ '''''[[Moxifloxacin]] 400 mg IV q24h'''''
 |}
 |}
-{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table13" style="background: #FFFFFF;"
+{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table52" style="background: #FFFFFF;"
+| valign=top |
+{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompetent patients}}
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]]  5/25 mg orally q12h X 3 days'''''
+|-
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]]  5/25 mg orally q12h X 5-7 days'''''
+|-
+|}
+|}
+{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table53" style="background: #FFFFFF;"
+| valign=top |
+{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompetent patients}}
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Erythromycin]] 500 mg orally q12h X 5 days'''''
+|-
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 160/800 mg orally q12h X 5-7 days'''''
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ofloxacin]] 300 mg orally q12h X 5-7 days'''''<BR> OR <BR> ▸ '''''[[Norfloxacin]] 400 mg orally q12h X 5-7 days'''''<BR> OR <BR> ▸ '''''[[Ciprofloxacin]] 500 mg orally q12h X 5-7 days'''''
+|-
+|}
+|}
+{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table54" style="background: #FFFFFF;"
+| valign=top |
+{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompetent patients}}
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Erythromycin]] 500 mg orally q12h X 5 days'''''
+|-
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 5/25 mg orally q12h X 5-7 days'''''
+|-
+|}
+|}
+{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table55" style="background: #FFFFFF;"
 | valign=top |
 {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
-! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Early (not yet infected)}}
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompetent patients}}
 |-
 | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
 |-
-| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Amoxicillin-clavulanate]] 45 mg/kg/day orally in two divided doses X 3-7 days'''''
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Erythromycin]] 500 mg orally q12h X 5 days'''''
 |-
-| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen (beta-lactam allergy)'''''
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
 |-
-| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Clindamycin]] 20 to 30 mg/kg/day orally in 4 divided doses'''''
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
 |-
-| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 160/800 mg orally q12h X 5-7 days'''''
 |-
-| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim]] component 8 mg/kg/day orally in 2 divided doses'''''
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
 |-
-! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Late (infected)}}
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ofloxacin]] 300 mg orally q12h X 5-7 days'''''<BR> OR <BR> ▸ '''''[[Norfloxacin]] 400 mg orally q12h X 5-7 days'''''<BR> OR <BR> ▸ '''''[[Ciprofloxacin]] 500 mg orally q12h X 5-7 days'''''
+|-
+|}
+|}
+{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table56" style="background: #FFFFFF;"
+| valign=top |
+{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompetent patients}}
 |-
 | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
 |-
-| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ampicillin sulbactam]] 100 to 300 mg/kg/day IV q6h'''''<BR> OR <BR> ▸ '''''[[Cefoxitin]] 80 to 160 mg/kg/day IV in 4 divided doses'''''<BR> OR <BR> ▸ '''''[[Ertapenem]] (3months - 12years) 15 mg/kg IV twice daily (maximum 1 g/day) OR [[Ertapenem]] (>13years) 1 g IV once daily'''''
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Erythromycin]] 500 mg orally q12h X 5 days'''''
+|-
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 5/25 mg orally q12h X 5-7 days'''''
 |-
 |}
 |}
-{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table22" style="background: #FFFFFF;"
+{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table57" style="background: #FFFFFF;"
+| valign=top |
+{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompetent patients}}
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''Unknown'''''
+|-
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen (For ETEC)'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ofloxacin]] 300 mg orally q12h X 5-7 days'''''<BR> OR <BR> ▸ '''''[[Norfloxacin]] 400 mg orally q12h X 5-7 days'''''<BR> OR <BR> ▸ '''''[[Ciprofloxacin]] 500 mg orally q12h X 5-7 days'''''
+|-
+|}
+|}
+{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table58" style="background: #FFFFFF;"
 | valign=top |
 {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
-! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Early (not yet infected)}}
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompetent patients}}
 |-
 | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
 |-
-| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Amoxicillin-clavulanate]] 875/125 mg orally q12h'''''<BR> OR <BR> ▸ '''''[[Amoxicillin-clavulanate]] 500/125 mg orally q8h'''''
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''Unknown'''''
 |-
-| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen (beta-lactam allergy)'''''
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
 |-
-| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Doxycycline]] 100 mg orally q12h'''''<BR> OR <BR> ▸ '''''[[Cefuroxime]] 500 mg orally q12h'''''
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
 |-
-! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Late (infected)}}
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''Unknown'''''
+|-
+|}
+|}
+{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table59" style="background: #FFFFFF;"
+| valign=top |
+{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompetent patients}}
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''Role of antibiotics unclear, and administration should be avoided'''''
+|-
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
 |-
 | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
 |-
-| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ampicillin sulbactam]] 1.5 to 3 g IV q6-8h'''''<BR> OR <BR> ▸ '''''[[Piperacillin-tazobactam]] 3.375 gm IV q6-8h'''''<BR> OR <BR> ▸ '''''[[Ertapenem]] 1 gm IV q24h'''''<BR> OR <BR> ▸ '''''[[Imipenem]]-[[Cilastin]] 1 gm IV q6-8h'''''<BR> OR <BR> ▸ '''''[[Imipenem]]-[[Cilastin]] 1 gm IV q6-8h'''''<BR> OR <BR> ▸ '''''[[Meropenem]] 1 gm IV q8h'''''
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''Role of antibiotics unclear, and administration should be avoided'''''
 |-
-| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen (beta-lactam allergy)'''''
+|}
+|}
+{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table60" style="background: #FFFFFF;"
+| valign=top |
+{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompetent patients}}
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
 |-
-| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Cefazolin]] 1 gm IV q8h'''''<BR> OR <BR> ▸ '''''[[Cefuroxime]] 1 gm IV q24h'''''<BR> OR <BR> ▸ '''''[[Cefoxitin]] 1 gm IV q6-8h'''''<BR> OR <BR>▸ '''''[[Ceftriaxone sodium]] 1 gm IV q12h'''''<BR> OR <BR>▸ '''''[[Cefotaxime]] 2 gm IV q6h'''''<BR> OR <BR>▸ '''''[[Ciprofloxacin]] 400 mg IV q12h'''''<BR> OR <BR>▸ '''''[[Moxifloxacin]] 400 mg IV q24h'''''
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''Role of antibiotics unclear, and administration should be avoided'''''
 |-
-! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Cat scratch disease}}
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
 |-
 | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
 |-
-| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Azithromycin]] 500 mg orally on day 1, then 250 mg orally once daily X 4 days'''''
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''Role of antibiotics unclear, and administration should be avoided'''''
 |-
 |}
 |}
-{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table23" style="background: #FFFFFF;"
+{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table61" style="background: #FFFFFF;"
 | valign=top |
 {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
-! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Early (not yet infected)}}
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompetent patients}}
 |-
 | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
 |-
-| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Amoxicillin-clavulanate]] 45 mg/kg/day orally in two divided doses X 3-7 days'''''
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]]  160/800 mg orally q12h X 3 days'''''
 |-
 | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
 |-
-| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Cefuroxime]] 10 to 15 mg/kg orally q12h'''''
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ofloxacin]] 300 mg orally q12h X 3 days'''''<BR> OR <BR> ▸ '''''[[Norfloxacin]] 400 mg orally q12h X 3 days'''''<BR> OR <BR> ▸ '''''[[Ciprofloxacin]] 500 mg orally q12h X 3 days'''''
 |-
-! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Cat scratch disease}}
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
 |-
 | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
 |-
-| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Azithromycin]] 10 mg/kg orally on day 1, then 5 mg/kg orally X 4 days'''''
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]]  160/800 mg orally q12h X 5-7 days'''''
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ofloxacin]] 300 mg orally q12h X 5-7 days'''''<BR> OR <BR> ▸ '''''[[Norfloxacin]] 400 mg orally q12h X 5-7 days'''''<BR> OR <BR> ▸ '''''[[Ciprofloxacin]] 500 mg orally q12h X 5-7 days'''''
 |-
 |}
 |}
-{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table13" style="background: #FFFFFF;"
+{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table62" style="background: #FFFFFF;"
 | valign=top |
 {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
-! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Late (infected)}}
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompetent patients}}
 |-
 | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
 |-
-| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ampicillin sulbactam]] 100 to 300 mg/kg/day IV q6h'''''<BR> OR <BR> ▸ '''''[[Cefoxitin]] 80 to 160 mg/kg/day IV in 4 divided doses'''''<BR> OR <BR> ▸ '''''[[Ertapenem]] (3months - 12years) 15 mg/kg IV twice daily (maximum 1 g/day) OR [[Ertapenem]] (>13years) 1 g IV once daily'''''
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 5/25 mg orally q12h X 3 days'''''
+|-
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 5/25 mg orally q12h X 5-7 days'''''
+|-
 |}
 |}
-{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table32" style="background: #FFFFFF;"
+{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table63" style="background: #FFFFFF;"
 | valign=top |
 {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
-! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|High risk bites (deep bites, symptomatic animals}}
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompetent patients}}
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen (Only for severe infections or bacteremia)'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Doxycycline]] 300 mg orally single dose'''''<BR> OR <BR> ▸ '''''[[Tetracycline]] 500 mg orally q6h X 3 days'''''
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 160/800 mg orally q12h X 5-7 days'''''<BR> OR <BR> ▸ '''''[[Ofloxacin]] 300 mg orally q12h X 5-7 days'''''<BR> OR <BR> ▸ '''''[[Norfloxacin]] 400 mg orally q12h X 5-7 days'''''<BR> OR <BR> ▸ '''''[[Ciprofloxacin]] 500 mg orally q12h X 5-7 days'''''
+|-
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
 |-
-| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen (without CNS symptoms)'''''
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
 |-
-| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Acyclovir]]  12.5–15 mg per kg IV q8h'''''<BR> OR <BR> ▸ '''''[[Ganciclovir]] 5 mg per kg IV q12h'''''
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Doxycycline]] 300 mg orally single dose'''''<BR> PLUS <BR> ▸ '''''[[Tetracycline]] 500 mg orally q6h X 3 days'''''
 |-
-| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen (with CNS symptoms)'''''
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 160/800 mg orally q12h X 5-7 days'''''<BR> OR <BR> ▸ '''''[[Ofloxacin]] 300 mg orally q12h X 5-7 days'''''<BR> OR <BR> ▸ '''''[[Norfloxacin]] 400 mg orally q12h X 5-7 days'''''<BR> OR <BR> ▸ '''''[[Ciprofloxacin]] 500 mg orally q12h X 5-7 days'''''
 |-
-| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ganciclovir]] 5 mg per kg IV q12h'''''
 |}
 |}
-{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table33" style="background: #FFFFFF;"
+{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table64" style="background: #FFFFFF;"
 | valign=top |
 {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
-! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|High risk bites (deep bites, symptomatic animals}}
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompetent patients}}
 |-
-| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen (without CNS symptoms)'''''
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen (Only for severe infections or bacteremia)'''''
 |-
-| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Acyclovir]]  12.5–15 mg per kg IV q8h'''''<BR> OR <BR> ▸ '''''[[Ganciclovir]] 5 mg per kg IV q12h'''''
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Doxycycline]] 300 mg orally single dose'''''<BR> OR <BR> ▸ '''''[[Tetracycline]] 500 mg orally q6h X 3 days'''''
 |-
-| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen (with CNS symptoms)'''''
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
 |-
-| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ganciclovir]] 5 mg per kg IV q12h'''''
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 5/25 mg orally q12h X 5-7 days'''''
+|-
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Doxycycline]] 300 mg orally single dose'''''<BR> PLUS <BR> ▸ '''''[[Tetracycline]] 500 mg orally q6h X 3 days'''''
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 5/25 mg orally q12h X 5-7 days'''''
 |-
 |}
 |}
-{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table42" style="background: #FFFFFF;"
+{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table65" style="background: #FFFFFF;"
 | valign=top |
 {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
-! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Uncomplicated}}
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompetent patients}}
 |-
 | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
 |-
-| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Amoxicillin-clavulanate]] 875/125 mg orally q12h'''''
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Doxycycline]] 300 mg orally single dose'''''<BR> OR <BR> ▸ '''''[[Tetracycline]] 500 mg orally q6h X 3 days'''''
 |-
-| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen (beta-lactam allergy)'''''
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
 |-
-| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Doxycycline]] 100 mg orally q12h'''''
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 160/800 mg orally q12h X 3 days'''''<BR> OR <BR> ▸ '''''[[Ofloxacin]] 300 mg orally q12h X 3 days'''''<BR> OR <BR> ▸ '''''[[Norfloxacin]] 400 mg orally q12h X 3 days'''''<BR> OR <BR> ▸ '''''[[Ciprofloxacin]] 500 mg orally q12h X 3 days'''''
 |-
-! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Rat bite fever}}
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
 |-
 | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
 |-
-| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Penicillin G benzathine]] 600,000 to 1,000,000 units/day IM X 10-14 days'''''<BR> OR <BR> ▸ '''''[[Tetracycline]]  250 to 500 mg orally q6h'''''
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Doxycycline]] 300 mg orally single dose'''''<BR> PLUS <BR> ▸ '''''[[Tetracycline]] 500 mg orally q6h X 3 days'''''
 |-
 | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
 |-
-| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Streptomycin]] 15 mg/kg/day IM in a single dose or in 2 divided doses X 10-14 days'''''
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 160/800 mg orally q12h X 5-7 days'''''<BR> OR <BR> ▸ '''''[[Ofloxacin]] 300 mg orally q12h X 5-7 days'''''<BR> OR <BR> ▸ '''''[[Norfloxacin]] 400 mg orally q12h X 5-7 days'''''<BR> OR <BR> ▸ '''''[[Ciprofloxacin]] 500 mg orally q12h X 5-7 days'''''
+|-
 |}
 |}
-{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table43" style="background: #FFFFFF;"
+{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table66" style="background: #FFFFFF;"
 | valign=top |
 {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
-! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Early (not yet infected)}}
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompetent patients}}
 |-
 | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
 |-
-| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Amoxicillin-clavulanate]] 45 mg/kg/day orally in two divided doses X 3-7 days'''''
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Doxycycline]] 300 mg orally single dose'''''<BR> OR <BR> ▸ '''''[[Tetracycline]] 500 mg orally q6h X 3 days'''''
 |-
 | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
 |-
-| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Cefuroxime]] 10 to 15 mg/kg orally q12h'''''
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 5/25 mg orally q12h X 5-7 days'''''
+|-
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Doxycycline]] 300 mg orally single dose'''''<BR> PLUS <BR> ▸ '''''[[Tetracycline]] 500 mg orally q6h X 3 days'''''
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 5/25 mg orally q12h X 5-7 days'''''
+|-
+|}
+|}
+{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table67" style="background: #FFFFFF;"
+| valign=top |
+{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompetent patients}}
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
 |-
-! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Rat bite fever}}
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Metronidazole]] 250 mg orally q6h X 10 days'''''<BR> OR <BR> ▸ '''''[[Metronidazole]] 500 mg orally q8h X 10 days'''''
+|-
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
 |-
 | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
 |-
-| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Penicillin G benzathine]] 25,000 to 50,000 units/day IM X 10-14 days'''''<BR> OR <BR> ▸ '''''[[Tetracycline]] (>8 years) 25 to 50 mg/kg/day orally in 4 divided doses X 10-14 days'''''
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Doxycycline]] 300 mg orally single dose'''''<BR> PLUS <BR> ▸ '''''[[Tetracycline]] 500 mg orally q6h X 3 days'''''
 |-
 | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
 |-
-| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Streptomycin]] 15 mg/kg/day IM in a single dose or in 2 divided doses X 10-14 days'''''
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 160/800 mg orally q12h X 5-7 days'''''<BR> OR <BR> ▸ '''''[[Ofloxacin]] 300 mg orally q12h X 5-7 days'''''<BR> OR <BR> ▸ '''''[[Norfloxacin]] 400 mg orally q12h X 5-7 days'''''<BR> OR <BR> ▸ '''''[[Ciprofloxacin]] 500 mg orally q12h X 5-7 days'''''
 |-
 |}
 |}
-{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table52" style="background: #FFFFFF;"
+{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table68" style="background: #FFFFFF;"
+| valign=top |
+{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompetent patients}}
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Metronidazole]] 250 mg orally q6h X 10 days'''''<BR> OR <BR> ▸ '''''[[Metronidazole]] 500 mg orally q8h X 10 days'''''
+|-
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Doxycycline]] 300 mg orally single dose'''''<BR> PLUS <BR> ▸ '''''[[Tetracycline]] 500 mg orally q6h X 3 days'''''
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 5/25 mg orally q12h X 5-7 days'''''
+|-
+|}
+|}
+{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table88" style="background: #FFFFFF;"
 | valign=top |
 {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
-! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Pig (Swine)}}
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompetent patients}}
 |-
 | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
 |-
-| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Amoxicillin-clavulanate]] 875/125 mg orally q12h X 5 days'''''
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Metronidazole]] 250-750 mg orally q8h X 7-10 days'''''
+|-
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Doxycycline]] 300 mg orally single dose'''''<BR> PLUS <BR> ▸ '''''[[Tetracycline]] 500 mg orally q6h X 3 days'''''
 |-
 | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
 |-
-| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ampicillin sulbactam]] '''''<BR> OR <BR> ▸ '''''[[Imipenem]]'''''<BR> OR <BR> ▸ '''''[[Cephalosporin]]'''''
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 160/800 mg orally q12h X 5-7 days'''''<BR> OR <BR> ▸ '''''[[Ofloxacin]] 300 mg orally q12h X 5-7 days'''''<BR> OR <BR> ▸ '''''[[Norfloxacin]] 400 mg orally q12h X 5-7 days'''''<BR> OR <BR> ▸ '''''[[Ciprofloxacin]] 500 mg orally q12h X 5-7 days'''''
 |-
 |}
 |}
-{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table53" style="background: #FFFFFF;"
+{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table89" style="background: #FFFFFF;"
 | valign=top |
 {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
-! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Pig (Swine)}}
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompetent patients}}
 |-
 | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
 |-
-| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Amoxicillin-clavulanate]] 875/125 mg orally q12h X 5 days'''''
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Metronidazole]] 250-750 mg orally q8h X 7-10 days'''''
+|-
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Doxycycline]] 300 mg orally single dose'''''<BR> PLUS <BR> ▸ '''''[[Tetracycline]] 500 mg orally q6h X 3 days'''''
 |-
 | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
 |-
-| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ampicillin sulbactam]] '''''<BR> OR <BR> ▸ '''''[[Imipenem]]'''''<BR> OR <BR> ▸ '''''[[Cephalosporin]]'''''
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 5/25 mg orally q12h X 5-7 days'''''
+|-
+|}
+|}
+{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table70" style="background: #FFFFFF;"
+| valign=top |
+{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompetent patients}}
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen (only if severe)'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Paromomycin]] 500 mg orally q8h X 7 days'''''
+|-
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Paromomycin]] 500 mg orally q8h X 14-28 days'''''<BR> THEN <BR> ▸ '''''[[Paromomycin]] 500 mg orally q12h X if needed'''''
 |-
 |}
 |}
-{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table62" style="background: #FFFFFF;"
+{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table71" style="background: #FFFFFF;"
+| valign=top |
+{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompetent patients}}
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen (only if severe)'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Paromomycin]] 500 mg orally q8h X 7 days'''''
+|-
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Paromomycin]] 500 mg orally q8h X 14-28 days'''''<BR> THEN <BR> ▸ '''''[[Paromomycin]] 500 mg orally q12h X if needed'''''
+|-
+|}
+|}
+{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table72" style="background: #FFFFFF;"
+| valign=top |
+{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompetent patients}}
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 160/800 mg orally q12h X 7-10 days'''''
+|-
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 160/800 mg orally q6h X 10 days'''''<BR> THEN <BR> ▸ '''''[[Trimethoprim-sulfamethoxazole]] 160/800 mg orally thrice weekly indefinitely'''''
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen (indefinitely for AIDS patients) '''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Sulfadoxine]] 500 mg'''''<BR> PLUS <BR>▸ '''''[[Pyrimethamine]] 25 mg'''''
+|-
+|}
+|}
+{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table73" style="background: #FFFFFF;"
+| valign=top |
+{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompetent patients}}
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 5/25 mg orally q12h X 7-10 days'''''
+|-
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 5/25 mg orally q6h X 10 days'''''<BR> THEN <BR> ▸ '''''[[Trimethoprim-sulfamethoxazole]] 5/25 mg orally thrice weekly indefinitely'''''
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen (indefinitely for AIDS patients) '''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Sulfadoxine]] 500 mg'''''<BR> PLUS <BR>▸ '''''[[Pyrimethamine]] 25 mg'''''
+|-
+|}
+|}
+{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table74" style="background: #FFFFFF;"
+| valign=top |
+{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompetent patients}}
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 160/800 mg orally q12h X 7 days'''''
+|-
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 160/800 mg orally q6h X 10 days'''''<BR> THEN <BR> ▸ '''''[[Trimethoprim-sulfamethoxazole]] 160/800 mg orally thrice weekly indefinitely'''''
+|-
+|}
+|}
+{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table75" style="background: #FFFFFF;"
+| valign=top |
+{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompetent patients}}
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 5/25 mg orally q12h X 7 days'''''
+|-
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 5/25 mg orally q6h X 10 days'''''<BR> THEN <BR> ▸ '''''[[Trimethoprim-sulfamethoxazole]] 5/25 mg orally thrice weekly indefinitely'''''
+|-
+|}
+|}
+{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table76" style="background: #FFFFFF;"
+| valign=top |
+{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompetent patients}}
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''Not determined'''''
+|-
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Albendazole]] 400 mg orally q12h X 21 days'''''
+|-
+|}
+|}
+{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table77" style="background: #FFFFFF;"
+| valign=top |
+{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompetent patients}}
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''Not determined'''''
+|-
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Albendazole]] 400 mg orally q12h X 21 days'''''
+|-
+|}
+|}
+{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table78" style="background: #FFFFFF;"
 | valign=top |
 {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
-! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Suspected Leptospirosis}}
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompetent patients}}
 |-
 | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
 |-
-| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Doxycycline]] 200 mg orally once within 72 hours of tick removal '''''
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Metronidazole]] 750 mg orally q8h X 5-10 days'''''<BR> PLUS <BR> ▸ '''''[[Diiodohydroxyquin]] 650 mg orally q8h X 20 days'''''
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Metronidazole]] 750 mg orally q8h X 5-10 days'''''<BR> PLUS <BR> ▸ '''''[[Paromomycin]] 500 mg orally q8h X 7 days'''''
+|-
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Metronidazole]] 750 mg orally q8h X 5-10 days'''''<BR> PLUS <BR> ▸ '''''[[Diiodohydroxyquin]] 650 mg orally q8h X 20 days'''''
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Metronidazole]] 750 mg orally q8h X 5-10 days'''''<BR> PLUS <BR> ▸ '''''[[Paromomycin]] 500 mg orally q8h X 7 days'''''
+|-
 |}
 |}
-{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table63" style="background: #FFFFFF;"
+{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table79" style="background: #FFFFFF;"
 | valign=top |
 {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
-! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Suspected Leptospirosis}}
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompetent patients}}
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Metronidazole]] 750 mg orally q8h X 5-10 days'''''<BR> PLUS <BR> ▸ '''''[[Diiodohydroxyquin]] 650 mg orally q8h X 20 days'''''
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Metronidazole]] 750 mg orally q8h X 5-10 days'''''<BR> PLUS <BR> ▸ '''''[[Paromomycin]] 500 mg orally q8h X 7 days'''''
+|-
+! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}}
 |-
 | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
 |-
-| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Doxycycline]] (≥8 years) 4 mg/kg (maximum 200 mg) orally once within 72 hours tick removal'''''
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Metronidazole]] 750 mg orally q8h X 5-10 days'''''<BR> PLUS <BR> ▸ '''''[[Diiodohydroxyquin]] 650 mg orally q8h X 20 days'''''
+|-
+| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
+|-
+| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Metronidazole]] 750 mg orally q8h X 5-10 days'''''<BR> PLUS <BR> ▸ '''''[[Paromomycin]] 500 mg orally q8h X 7 days'''''
 |-
 |}
@@ Line 529: / Line 1,112: @@
 [[Category:Emergency medicine]]
-[[Category:Infectious disease]]
-[[Category:Injuries]]
-[[Category:Primary care]]
-[[Category:Veterinary medicine]]

Sandbox/diarrhea: Difference between revisions

Latest revision as of 06:39, 28 July 2020

Pathogen Specific

References

Navigation menu